

Catalytic Enantioselective Cyclization and C3-Fluorination of Polyenes

Nikki A. Cochrane, Ha Nguyen, and Michel R. Gagne*

Department of Chemistry, University of North Carolina at Chapel Hill, CB # 3290, Chapel Hill, North Carolina 27599, United States

Supporting Information

ABSTRACT: (Xylyl-phanephos)Pt²⁺ in combination with XeF₂ mediates the consecutive diastereoselective cation-olefin cyclization/fluorination of polyene substrates. Isolated yields were typically in the 60-69% range while enantioselectivities reached as high as 87%. The data are consistent with a stereoretentive fluorination of a P₂Pt-alkyl cation intermediate.

The fluorination of pharmaceutical drug candidates is an important strategy for masking metabolic hot spots. Despite recent progress with electrophilic fluorinating reagents, the synthesis of such compounds is still challenging and many deficiencies remain, especially in the asymmetric fluorination of nonenolate-based carbon nucleophiles. Fluorinated steroids (Scheme 1), in particular, are important bioactive compounds with a deficiency of methods for their synthesis. 6–8

De novo syntheses of carbocycles with the flexibility for F-incorporation are rare, though such methods would considerably expand the accessibility of such privileged structures. Transition metal catalyzed cyclizations, if suitably coupled to M–C fluorination reactions, could provide a route to complex fluorinated carbo- and heterocycles with control of absolute and relative stereochemistry.

Electrophilic Pt(II) complexes are effective initiators of C–C bond forming cation-olefin cascades. P11 The fate of the organometallic intermediate of these cascades can be controlled through ligand choice, and when the supporting ligand is a diphosphine, this intermediate is susceptible to β -H elimination and leads to net dehydrogenated products. If this complex could instead be intercepted by a Pt–C fluorination reaction, a catalytic cyclization/fluorination protocol would result with concomitant access to C3-fluorinated compounds. The rapidity and stereospecificity with which [(triphos)Pt–R][BF4] reacts with XeF2 to yield C–F products (eq. 1)

Scheme 1. Common Fluorinated Steroids




Table 1. Selected Optimizing Conditions

^aUncorrected GC percentages. ^bDetermined by chiral GC.

suggested that the desired interception might be capable of competing with $\beta\text{-H}$ elimination. 12

In the diphosphine catalyst series that we have examined, (S)-xylyl-phanephos ((S)-(-)-4,12-bis[di(3,5-xylyl)-phosphine]-[2,2]-paracyclophane) has consistently provided the highest enantioselectivity for various cyclization chemistries. As a starting point for our catalytic cyclization/fluorination goal, we adapted conditions previously optimized for cyclization/ β -H elimination reactions. ^{10b} The modified conditions included use of AgBF₄ and NCC₆F₅ to generate the "active" [(S)-(xylyl-phanephos)Pt(NCC₆F₅)₂][(BF₄)₂] catalyst. Subsequent addition of a base (to facilitate cyclization), substrate, and an electrophilic fluorine source generated the desired product (1) as a single (stereoretentive) isomer, along with variable quantities of β -H eliminated product (3) and the Brønsted product (5) (Table 1); several additional phosphines are included for comparison.

Received: November 29, 2012 Published: January 2, 2013

Scheme 2. Proposed Catalytic Cycle for Electrophilic Fluorination

$$[Pt] = (S)-(xylyl-phanephos)Pt$$

$$[Pt]^{2+}$$

$$[Pt]^{2+}$$

$$[Pt]^{-1}$$

$$[Pt]^{-$$

In screening a variety of electrophilic fluorine sources, it was discovered that only XeF_2 effectively competed with β -H elimination. Other less reactive F^+ sources showed a predominance to exclusive β -H elimination to 3. In addition to the desired 1, over-fluorination to 4 was also observed. Since controls showed that 1 does not react with XeF_2 and acid is known to enhance the F^+ potential of XeF_2 , YeF_2 we surmised that the HF byproduct of cyclization was activating the XeF_2 . This problem was easily solved by the addition of TMSOMe as an HF sponge, which additionally obviates the need for a base.

6

Optimization studies included testing multiple bisphosphines, solvents, and other TMS-X derivatives. Once again (S)-xylyl-phanephos was uniquely enantioselective (\sim 75%) for controlling the % ee of the cation-olefin cascades. Of the tested HF scavengers, TMSOMe was the most effective inhibitor of double fluorination, and like previous ionic cascades, nitromethane was the optimum solvent. A catalyst formulation comprised of 10 mol % (S)-(xylyl-phanephos)PtI₂, 25 mol % AgBF₄, 30 mol % NCC₆F₅, and stoichiometric quantities of XeF₂ and TMSOMe at 0 °C provided 1 in 67% yield and with a 75% enantiometric excess. ¹⁶

These optimized conditions were subsequently applied to a variety of alcohol and phenol terminated dienes and trienes (Table 2). In most cases, a high conversion of substrate occurred within 3 h; however, the reactions were allowed to proceed for 24 h at 0 $^{\circ}$ C to ensure complete consumption of the XeF₂. For the substrate classes in Table 2, no Brønsted acid derived products such as 5 were observed, and a single diastereomer consistent with stereoretentive fluorination of the intermediate P₂Pt-alkyl cation was observed.

As shown in Table 2, variants on the phenol termini were well tolerated, except for α -naphthol (entry 3), wherein competitive fluorination of the aryl ether product occurs even with TMSOMe. In situ monitoring indicated that aryl fluorination occurred after cyclization/Pt-C fluorination. In this case, extra XeF₂ was used to compensate for the difluorination stoichiometry. Unexpectedly, *para*-substituents improved the ee's (entries 4–7).

Dienyl and trienyl alcohols and phenols were also viable substrates though they behaved peculiarly. In the case of entries 8 and 9, the yields were poor under standard conditions but could be recovered by exchanging TMSOMe for a polystyrene-bound piperidine base (see Table 1). In contrast, the triene

Table 2. Catalytic Electrophilic Fluorination^a

^aConditions: 10 mol % (*S*)-(xylyl-phanephos)PtI₂, 25 mol % AgBF₄, 30 mol % NCC₆F₅, 1.1 equiv of TMS-OMe, 1.1 equiv of XeF₂, 0.4 mL of CD₃NO₂, 0 °C, 24 h. Starting material is mass balance of reaction. ^bIsolated yield, % ee determined by chiral GC. ^cGC yield. ^dReaction run using 1.6 equiv of XeF₂. ^ePercentage is fluorinated elimination species only. ^fReaction with 20 mol % polystyrene-bound piperidine base run with no TMS-OMe; see SI for details. ^gDue to the volatility of this compound, a GC yield is reported. ^hContains 23% unidentified species; mass balance is unreacted starting materisl. Cannot separate the unidentified species from the product; therefore GC yield is reported.

alcohol in entry 10 performed better under the standard conditions. These base effects are not yet understood.

In situ monitoring of a cyclization/fluorination of **2** indicated that the alkyl cation (as the nitrile adduct, **6**) serves as the catalyst resting state (^{31}P NMR). These data support our current view of the mechanism (Scheme 2) that has **6** competitively undergoing β -H elimination or F^+ attack to generate a $[Pt]^{IV}R(F)$ dication, which undergoes a stereoretentive reductive elimination to **1**. Neither the $[Pt]^{IV}$ nor the

[Pt]—H species are observable by NMR; however, literature precedence suggests that both routes are viable. $^{\rm 5d,f,i,k,17}$

In summary, we illustrate that P₂Pt-dicationic catalysts can mediate the enantioselective cation-olefin cyclization/fluorination reactions of polyenes to yield C3-fluorinated carbocycles. The key feature of the putative catalytic cycle is the selective reaction of XeF₂ with P₂Pt-alkyl cations over P₂Pt-dications, which enables the sequential cyclization/fluorination.

ASSOCIATED CONTENT

S Supporting Information

Characterization data for all new compounds and synthetic procedures are included in the Supporting Information. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author

mgagne@unc.edu

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We thank Prof. M. S. Brookhart for insightful comments and the National Institute of General Medical Sciences for generous support (Grant GM-60578). H. N. also thanks the VEF for their support.

REFERENCES

- (1) (a) Hiyama, T. Organofluorine Compounds; Springer: Berlin, 2000. (b) Hagmann, W. K. J. Med. Chem. 2008, 51, 4359. (c) Furuya, T.; Kuttruff, C. A.; Ritter, T. Curr. Opin. Drug Discovery 2008, 11, 803. and references therein. (d) Kirk, K. L. Org. Process Res. Dev. 2008, 12, 305. (e) Purser, S.; Moore, P. R.; Swallow, S.; Gouverneur, V. Chem. Soc. Rev. 2008, 37, 320. (f) Morgenthaler, M.; Schweizer, E.; Hoffmann-Röder, A.; Benini, F.; Martin, R. E.; Jaeschke, G.; Wagner, B.; Fischer, H.; Bendels, S.; Zimmerli, D.; Schneider, J.; Diederich, F.; Kansy, M.; Müller, K. ChemMedChem 2007, 2, 1100. (g) Müller, K.; Faeh, C.; Diederich, F. Science 2007, 317, 1881.
- (2) For aromatic electrophilic fluorinations, see for example: (a) Grushin, V. V. Acc. Chem. Res. 2010, 43, 160. (b) Gouverneur, V. Nat Chem 2012, 4, 152. (c) Borodkin, G. I.; Shubin, V. G. Russ. Chem. Rev. 2010, 79, 259. (d) Fier, P. S.; Hartwig, J. F. J. Am. Chem. Soc. 2012, 134, 10795. (e) Chan, K. S. L.; Wasa, M.; Wang, X.; Yu, J.-Q. Angew. Chem., Int. Ed. 2011, 50, 9081. (f) Tang, P.; Furuya, T.; Ritter, T. J. Am. Chem. Soc. 2010, 132, 12150. (g) Wang, X.; Mei, T.-S.; Yu, J.-Q. J. Am. Chem. Soc. 2009, 131, 7520. (h) Furuya, T.; Kaiser, H. M.; Ritter, T. Angew. Chem., Int. Ed. 2008, 47, 5993. (i) Hull, K. L.; Anani, W. Q.; Sanford, M. S. J. Am. Chem. Soc. 2006, 128, 7134.
- (3) For enantioselective fluorination reviews: (a) Cahard, D.; Xu, X.; Couve-Bonnaire, S.; Pannecoucke, X. Chem. Soc. Rev. 2010, 39, 558. (b) Lectard, S.; Hamashima, Y.; Sodeoka, M. Adv. Synth. Catal. 2010, 352, 2708. (c) Ma, J.-A.; Cahard, D. Chem. Rev. 2008, 108, PR1. (d) Pihko, P. M. Angew. Chem., Int. Ed. 2006, 45, 544. (e) Audouard, C.; Ma, J. A.; Cahard, D. Adv. Org. Synth. 2006, 2, 431.
- (4) For nonenolate organic enantioselective electrophilic fluorinations: (a) Rauniyar, V.; Lackner, A. D.; Hamilton, G. L.; Toste, F. D. Science 2011, 334, 1681. (b) Dinoiu, V. Rev. Roum. Chim. 2007, 52, 219. (c) Kim, S. M.; Kang, Y. K.; Cho, M. J.; Mang, J. Y.; Kim, D. Y. Bull. Korean Chem. Soc. 2007, 28, 2435. (d) Togni, A.; Mezzetti, A.; Barthazy, P.; Becker, C.; Devillers, I.; Frantz, R.; Hintermann, L.; Perseghini, M.; Sanna, M. Chimia 2001, 55, 801. (e) Qiu, S.; Xu, T.; Zhou, J.; Guo, Y.; Liu, G. J. Am. Chem. Soc. 2010, 132, 2856.
- (5) For electrophilic fluorinations that proceed through M-C bonds, see for examples: (a) Furuya, T.; Kamlet, A. S.; Ritter, T. *Nature* **2011**, 473, 470. (b) Vigalok, A. *Organometallics* **2011**, 30, 4802. (c) Engle, K.

- M.; Mei, T.-S.; Wang, X.; Yu, J.-Q. Angew. Chem., Int. Ed. 2011, 50, 1478. (d) Vigalok, A.; Kaspi, A. W. Top. Organomet. Chem. 2010, 31, 19. (e) Mankad, N. P.; Toste, F. D. Chem. Sci. 2012, 3, 72. (f) Racowski, J. M.; Gary, J. B.; Sanford, M. S. Angew. Chem., Int. Ed. 2012, 51, 3414. (g) Dubinsky-Davidchik, I. S.; Potash, S.; Goldberg, I.; Vigalok, A.; Vedernikov, A. N. J. Am. Chem. Soc. 2012, 134, 14027. (h) Bloom, S.; Pitts, C. R.; Miller, D. C.; Haselton, N.; Holl, M. G.; Urheim, E.; Lectka, T. Angew. Chem., Int. Ed. 2012, 51, 10580. (i) Furuya, T.; Benitez, D.; Tkatchouk, E.; Strom, A. E.; Tang, P.; Goddard, W. A.; Ritter, T. J. Am. Chem. Soc. 2010, 132, 3793. (j) Furuya, T.; Klein, J. E. M. N.; Ritter, T. Synthesis 2010, 11, 1804. (k) Ball, N. D.; Sanford, M. S. J. Am. Chem. Soc. 2009, 131, 3796. (1) Kaspi, A. W.; Yahav-Levi, A.; Goldberg, I.; Vigalok, A. Inorg. Chem. 2008, 47, 5. (m) Hull, K. L.; Anani, W. Q.; Sanford, M. S. J. Am. Chem. Soc. 2006, 128, 7134. (n) Dick, A. R.; Kampf, J. W.; Sanford, M. S. J. Am. Chem. Soc. 2005, 127, 12790.
- (6) For steroid fluorination see for example: (a) Poss, A. J.; Shia, G. A. Tet. Lett. 1995, 36, 4721. (b) Rozen, S.; Ben-Shushan, G. J. Org. Chem. 1986, 51, 3522. (c) Bowers, A.; Ringold, H. J. Tetrahedron 1958, 3, 14. (d) For C3 fluorinated steroids: Liu, W.; Huang, X.; Cheng, M.-J.; Nielsen, R. J.; Goddard, W. A.; Groves, J. T. Science 2012, 337, 1322.
- (7) For a recent enantioselective I⁺ initiated cascade to yield C3-halopolyprenoids, see: (a) Chen, G.; Ma, S. *Angew. Chem., Int. Ed.* **2010**, 49, 8306. (b) Sakakura, A.; Ukai, A.; Ishihara, K. *Nature* **2007**, 445, 900. (c) Sakakura, A.; Ishihara, K. *ChimicaOggi-Chemistry Today* **2007**, 25, 9.
- (8) For asymmetric polyolefin cyclization methodologies, see: (a) Zhu, S.; MacMillan, D. W. C. J. Am. Chem. Soc. 2012, 134, 10815. (b) Schafroth, M. A.; Sarlah, D.; Krautwald, S.; Carreira, E. M. J. Am. Chem. Soc. 2012, 134, 20276. (c) Jones, S. B.; Simmons, B.; Mastracchio, A.; MacMillan, D. W. C. Nature 2011, 475, 183. (d) Rendler, S.; MacMillan, D. W. C. J. Am. Chem. Soc. 2010, 132, 5027. (e) Knowles, R. R.; Lin, S.; Jacobsen, E. N. J. Am. Chem. Soc. 2010, 132, 5030. (f) Knowles, R. R.; Jacobsen, E. N. Proc. Natl. Acad. Sci. 2010, 107, 20678. (g) Surendra, K.; Corey, E. J. J. Am. Chem. Soc. 2008, 130, 8865. (h) Zhao, Y.-J.; Loh, T.-P. J. Am. Chem. Soc. 2008, 130, 10024. (i) Uyanik, M.; Ishibara, K.; Yamamoto, H. Org. Lett. 2006, 8, 5649. (j) Uyanik, M.; Ishibashi, H.; Ishihara, K.; Yamamoto, H. Org. Lett. 2005, 7, 1601. (k) Taylor, M. S.; Jacobsen, E. N. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 5368. (l) Kang, S. H.; Lee, S. B.; Park, C. M. J. Am. Chem. Soc. 2003, 125, 15748.
- (9) (a) Fürstner, A. Chem. Soc. Rev. 2009, 38, 3208. (b) Fürstner, A.; Davies, P. W. Angew. Chem., Int. Ed. 2007, 46, 3410. (c) Chianese, A. R.; Lee, S. J.; Gagné, M. R. Angew. Chem., Int. Ed. 2007, 46, 4042.
- (10) (a) Sokol, J. G.; Korapala, C. S.; White, P. S.; Becker, J. J.; Gagné, M. R. Angew. Chem., Int. Ed. 2011, 50, 5658. (b) Mullen, C. A.; Campbell, A. N.; Gagné, M. R. Angew. Chem., Int. Ed. 2008, 47, 6011. (c) Mullen, C. A.; Gagné, M. R. J. Am. Chem. Soc. 2007, 129, 11880. (d) Kerber, W. D.; Gagné, M. R. Org. Lett. 2005, 7, 3379. (e) Koh, J. H.; Gagné, M. R. Angew. Chem., Int. Ed. 2004, 43, 3459. (f) Kerber, W. D.; Koh, J. H.; Gagné, M. R. Org. Lett. 2004, 6, 3013. (g) Koh, J. H.; Larsen, A. O.; Gagné, M. R. Org. Lett. 2001, 3, 1233.
- (11) For related electrophilic polyene cyclizations: (a) Pradal, A.; Chen, Q.; Faudot dit Bel, P.; Toullec, P. Y.; Michelet, V. Synlett 2012, 23, 74. (b) Peng, H.; Liu, G. Org. Lett. 2011, 13, 772. (c) Chen, C.-C.; Yang, S.-C.; Wu, M.-J. J. Org. Chem. 2011, 76, 10269. (d) Toullec, P.; Michelet, V.; Soriano, E.; Marco-Contelles, J. In Topics in Current Chemistry; Springer: Berlin/Heidelberg, 2011; Vol. 302; pp 31. (e) Sethofer, S. G.; Mayer, T.; Toste, F. D. J. Am. Chem. Soc. 2010, 132, 8276. (f) Toullec, P. Y.; Blarre, T.; Michelet, V. Org. Lett. 2009, 11, 2888.
- (12) Zhao, S.-B.; Becker, J. J.; Gagné, M. R. Organometallics 2011, 30, 3926.
- (13) A comprehensive list of F⁺ reagents and TMS-X sources tested during optimization is available in the Supporting Information.
- (14) (a) Tius, M. A. Tetrahedron 1995, 51, 6605. (b) Tramšek, M.; Žemva, B. J. Fluorine Chem. 2006, 127, 1275.

- (15) NMR data and a comprehensive list of tested silyl ethers are available in the Supporting Information.
- (16) Note that in the absence of [Pt] no conversion of starting material was observed.
- (17) (a) Zhao, S.-B.; Wang, R.-Y.; Nguyen, H.; Becker, J. J.; Gagné, M. R. Chem. Commun. 2012, 48, 443. (b) Grice, K.; Scheuermann, M.; Goldberg, K.; Canty, A. J. In Top. Organomet. Chem.; Springer: Berlin/Heidelberg, 2011; Vol. 503; pp 1. (c) Yahav-Levi, A.; Goldberg, I.; Vigalok, A. J. Fluorine Chem. 2010, 131, 1100. (d) Furuya, T.; Ritter, T. J. Am. Chem. Soc. 2008, 130, 10060. (e) Wang, T.; Love, J. A. Organometallics 2008, 27, 3290.